Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making

Haley K. Perlow, Vincent Cassidy, Benjamin Farnia, Deukwoo Kwon, Adam W. Awerbuch, Stephanie Ciraula, Scott Alford, Jacob Griggs, Joseph A. Quintana, Raphael Yechieli, Stuart E. Samuels

Research output: Contribution to journalArticle

Abstract

Purpose: Previous studies have indicated a relationship between functional status and comorbidity on overall survival when treating patients with bone and brain metastases. However, the degree to which these findings have been integrated into modern-day practice remains unknown. This study examines the impact of performance measures, including Karnofsky Performance Status (KPS) and comorbidity, on palliative radiation therapy treatment tolerance and fractionation schedule. The relationship between a shorter fractionation schedule (SFx) and pending mortality is examined. Methods and materials: This study included patients who were treated with palliative intent to the brain or bone between January 1, 2016 and June 30, 2016. Demographic and medical characteristics collected included KPS score (stratified as good [90-100], fair [70-80], and poor (≤60]), socioeconomic status, comorbidity (binary measure using the Adult Comorbidity Evaluation-27 scale), site of metastatic disease, and treatment facility. Univariable analyses were performed using the Cox proportional hazards regression model to assess the impact of the variables on the prescribed number of fractions (binary measure, ≥10 [long fractionation schedule], and <10 [SFx]), and major treatment interruptions (MTIs; defined as missing ≥3 radiation therapy treatment days or ending treatment prematurely). Results: A total of 145 patients were eligible for study inclusion, including 95 patients who were treated for bony metastatic disease and 50 patients for brain metastases. High comorbidity (P =.029) and both fair (P =.051) and poor (P =.065) functional status were associated with more frequent MTIs. However, high comorbidity and low KPS score were not associated with shorter treatment plans. In addition, patients with an earlier time to death were not more likely to receive an SFx (P =.871). Conclusions: Low KPS and elevated comorbidity scores predict for a poorer prognosis and more frequent MTIs; however, there was no indication that physicians incorporated this information in the fractionation scheduling.

Original languageEnglish (US)
JournalAdvances in Radiation Oncology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Radiation Tolerance
Palliative Care
Comorbidity
Decision Making
Karnofsky Performance Status
Appointments and Schedules
Brain
Radiotherapy
Therapeutics
Neoplasm Metastasis
Bone and Bones
Proportional Hazards Models
Social Class
Demography
Physicians
Survival
Mortality

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making. / Perlow, Haley K.; Cassidy, Vincent; Farnia, Benjamin; Kwon, Deukwoo; Awerbuch, Adam W.; Ciraula, Stephanie; Alford, Scott; Griggs, Jacob; Quintana, Joseph A.; Yechieli, Raphael; Samuels, Stuart E.

In: Advances in Radiation Oncology, 01.01.2018.

Research output: Contribution to journalArticle

Perlow, Haley K. ; Cassidy, Vincent ; Farnia, Benjamin ; Kwon, Deukwoo ; Awerbuch, Adam W. ; Ciraula, Stephanie ; Alford, Scott ; Griggs, Jacob ; Quintana, Joseph A. ; Yechieli, Raphael ; Samuels, Stuart E. / Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making. In: Advances in Radiation Oncology. 2018.
@article{8ed2c170b3b1461e86125c32c83de713,
title = "Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making",
abstract = "Purpose: Previous studies have indicated a relationship between functional status and comorbidity on overall survival when treating patients with bone and brain metastases. However, the degree to which these findings have been integrated into modern-day practice remains unknown. This study examines the impact of performance measures, including Karnofsky Performance Status (KPS) and comorbidity, on palliative radiation therapy treatment tolerance and fractionation schedule. The relationship between a shorter fractionation schedule (SFx) and pending mortality is examined. Methods and materials: This study included patients who were treated with palliative intent to the brain or bone between January 1, 2016 and June 30, 2016. Demographic and medical characteristics collected included KPS score (stratified as good [90-100], fair [70-80], and poor (≤60]), socioeconomic status, comorbidity (binary measure using the Adult Comorbidity Evaluation-27 scale), site of metastatic disease, and treatment facility. Univariable analyses were performed using the Cox proportional hazards regression model to assess the impact of the variables on the prescribed number of fractions (binary measure, ≥10 [long fractionation schedule], and <10 [SFx]), and major treatment interruptions (MTIs; defined as missing ≥3 radiation therapy treatment days or ending treatment prematurely). Results: A total of 145 patients were eligible for study inclusion, including 95 patients who were treated for bony metastatic disease and 50 patients for brain metastases. High comorbidity (P =.029) and both fair (P =.051) and poor (P =.065) functional status were associated with more frequent MTIs. However, high comorbidity and low KPS score were not associated with shorter treatment plans. In addition, patients with an earlier time to death were not more likely to receive an SFx (P =.871). Conclusions: Low KPS and elevated comorbidity scores predict for a poorer prognosis and more frequent MTIs; however, there was no indication that physicians incorporated this information in the fractionation scheduling.",
author = "Perlow, {Haley K.} and Vincent Cassidy and Benjamin Farnia and Deukwoo Kwon and Awerbuch, {Adam W.} and Stephanie Ciraula and Scott Alford and Jacob Griggs and Quintana, {Joseph A.} and Raphael Yechieli and Samuels, {Stuart E.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.adro.2018.09.002",
language = "English (US)",
journal = "Advances in Radiation Oncology",
issn = "2452-1094",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Impact of Performance Status and Comorbidity on Palliative Radiation Treatment Tolerance and End-Of-Life Decision-Making

AU - Perlow, Haley K.

AU - Cassidy, Vincent

AU - Farnia, Benjamin

AU - Kwon, Deukwoo

AU - Awerbuch, Adam W.

AU - Ciraula, Stephanie

AU - Alford, Scott

AU - Griggs, Jacob

AU - Quintana, Joseph A.

AU - Yechieli, Raphael

AU - Samuels, Stuart E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose: Previous studies have indicated a relationship between functional status and comorbidity on overall survival when treating patients with bone and brain metastases. However, the degree to which these findings have been integrated into modern-day practice remains unknown. This study examines the impact of performance measures, including Karnofsky Performance Status (KPS) and comorbidity, on palliative radiation therapy treatment tolerance and fractionation schedule. The relationship between a shorter fractionation schedule (SFx) and pending mortality is examined. Methods and materials: This study included patients who were treated with palliative intent to the brain or bone between January 1, 2016 and June 30, 2016. Demographic and medical characteristics collected included KPS score (stratified as good [90-100], fair [70-80], and poor (≤60]), socioeconomic status, comorbidity (binary measure using the Adult Comorbidity Evaluation-27 scale), site of metastatic disease, and treatment facility. Univariable analyses were performed using the Cox proportional hazards regression model to assess the impact of the variables on the prescribed number of fractions (binary measure, ≥10 [long fractionation schedule], and <10 [SFx]), and major treatment interruptions (MTIs; defined as missing ≥3 radiation therapy treatment days or ending treatment prematurely). Results: A total of 145 patients were eligible for study inclusion, including 95 patients who were treated for bony metastatic disease and 50 patients for brain metastases. High comorbidity (P =.029) and both fair (P =.051) and poor (P =.065) functional status were associated with more frequent MTIs. However, high comorbidity and low KPS score were not associated with shorter treatment plans. In addition, patients with an earlier time to death were not more likely to receive an SFx (P =.871). Conclusions: Low KPS and elevated comorbidity scores predict for a poorer prognosis and more frequent MTIs; however, there was no indication that physicians incorporated this information in the fractionation scheduling.

AB - Purpose: Previous studies have indicated a relationship between functional status and comorbidity on overall survival when treating patients with bone and brain metastases. However, the degree to which these findings have been integrated into modern-day practice remains unknown. This study examines the impact of performance measures, including Karnofsky Performance Status (KPS) and comorbidity, on palliative radiation therapy treatment tolerance and fractionation schedule. The relationship between a shorter fractionation schedule (SFx) and pending mortality is examined. Methods and materials: This study included patients who were treated with palliative intent to the brain or bone between January 1, 2016 and June 30, 2016. Demographic and medical characteristics collected included KPS score (stratified as good [90-100], fair [70-80], and poor (≤60]), socioeconomic status, comorbidity (binary measure using the Adult Comorbidity Evaluation-27 scale), site of metastatic disease, and treatment facility. Univariable analyses were performed using the Cox proportional hazards regression model to assess the impact of the variables on the prescribed number of fractions (binary measure, ≥10 [long fractionation schedule], and <10 [SFx]), and major treatment interruptions (MTIs; defined as missing ≥3 radiation therapy treatment days or ending treatment prematurely). Results: A total of 145 patients were eligible for study inclusion, including 95 patients who were treated for bony metastatic disease and 50 patients for brain metastases. High comorbidity (P =.029) and both fair (P =.051) and poor (P =.065) functional status were associated with more frequent MTIs. However, high comorbidity and low KPS score were not associated with shorter treatment plans. In addition, patients with an earlier time to death were not more likely to receive an SFx (P =.871). Conclusions: Low KPS and elevated comorbidity scores predict for a poorer prognosis and more frequent MTIs; however, there was no indication that physicians incorporated this information in the fractionation scheduling.

UR - http://www.scopus.com/inward/record.url?scp=85055207458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055207458&partnerID=8YFLogxK

U2 - 10.1016/j.adro.2018.09.002

DO - 10.1016/j.adro.2018.09.002

M3 - Article

AN - SCOPUS:85055207458

JO - Advances in Radiation Oncology

JF - Advances in Radiation Oncology

SN - 2452-1094

ER -